Drug intelligence / Profile preview

TNX-2300

Development stage: Preclinical
Lead developer: Tonix Pharmaceuticals
Modality: Vaccines & Immunotherapeutics
Administration: Intranasal

Overview

TNX-2300 is a preclinical live attenuated virus vaccine candidate being developed by Tonix Pharmaceuticals in collaboration with Kansas State University for the prevention of COVID-19. The vaccine utilizes a novel bovine parainfluenza (BPI) virus vector platform designed for mucosal (intranasal) administration. It is engineered to express the SARS-CoV-2 spike protein to elicit neutralizing antibodies and co-express CD40-ligand (CD40L) to enhance T cell-mediated immunity. The program aims to provide durable immunity and prevent forward transmission of the virus by stimulating local mucosal immune responses.

Targets

SARS-CoV-2 spikeCD40 (Cluster of differentiation 40 receptor)

Beyond the preview

Go deeper on TNX-2300.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TNX-2300.

Explore the full profile